ORUKA THERAPEUTICS INC(ORKA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORKA ORUKA THERAPEUTICS INC

Closed Independence Day 07-02 16:00:00 EDT

85.21

-8.08

-8.66%

盘后86.91

+1.70+2.00%

18:55 EDT

High91.78	Low82.22	Vol4.52M
Open90.84	D1 Closing93.29	Amplitude10.25%
Mkt Cap5.14B	Tradable Cap4.08B	Total Shares60.31M
T/O381.13M	T/O Rate9.45%	Tradable Shares47.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORKA","market":"US","secType":"STK","nameCN":"ORUKA THERAPEUTICS INC","latestPrice":85.21,"timestamp":1783022400000,"preClose":93.29,"halted":0,"volume":4523960,"hourTrading":{"tag":"盘后","latestPrice":86.91,"preClose":85.21,"latestTime":"18:55 EDT","volume":3909,"amount":333171.37,"timestamp":1783032918856,"change":1.7,"changeRate":0.019951,"amplitude":0.019951},"delay":0,"changeRate":-0.08661164111909113,"floatShares":47879500,"shares":60312101,"eps":-2.32,"marketStatus":"Closed Independence Day","change":-8.08,"latestTime":"07-02 16:00:00 EDT","open":90.84,"high":91.78,"low":82.2201,"amount":381125787.50176,"amplitude":0.102475,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.32,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"listingDate":871012800000,"exchange":"NASDAQ","adjPreClose":93.29,"preHourTrading":{"tag":"盘前","latestPrice":89.62,"preClose":93.29,"latestTime":"09:25 EDT","volume":1452,"amount":130769.93688000001,"timestamp":1782998700008,"change":-3.67,"changeRate":-0.03934,"amplitude":0.068389},"postHourTrading":{"tag":"盘后","latestPrice":86.91,"preClose":85.21,"latestTime":"18:55 EDT","volume":3909,"amount":333171.37,"timestamp":1783032918856,"change":1.7,"changeRate":0.019951,"amplitude":0.019951},"volumeRatio":1.964421,"impliedVol":0.966,"impliedVolPercentile":0.506},"requestUrl":"/m/hq/s/ORKA/tweets","defaultTab":"tweets","newsList":[{"id":"1166983973","title":"Movement Alert｜Oruka Therapeutics Falls 11.21% in Regular Trading, Trading at $83.215","url":"https://stock-news.laohu8.com/highlight/detail?id=1166983973","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166983973?lang=en_us&edition=fundamental","pubTime":"2026-07-03 03:14","pubTimestamp":1783019658,"startTime":"0","endTime":"0","summary":"On July 3, Oruka Therapeutics fell 11.21% in regular trading, trading at $83.215 USD/share, with Turnover of $319 million.Within the Biotechnology sector where Oruka Therapeutics belongs, the overall...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648683292","title":"Oruka Therapeutics falls -8.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648683292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648683292?lang=en_us&edition=fundamental","pubTime":"2026-07-02 22:05","pubTimestamp":1783001125,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) is down -8.1%, or -$7.60 to $85.69. Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-falls-8-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-falls-8-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648222975","title":"Oruka Therapeutics COO Laura Lee Sandler Sells USD 472,784 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648222975","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648222975?lang=en_us&edition=fundamental","pubTime":"2026-07-02 07:58","pubTimestamp":1782950319,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics COO Laura Lee Sandler sells USD 472,784 in common sharesOruka Therapeutics COO Laura Lee Sandler reported net sales of 5,000 common shares on July 1, 2026.She sold 5,000 shares at w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL788Fnq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka Therapeutics COO Laura Lee Sandler Sells USD 472,784 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648791544","title":"Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2648791544","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648791544?lang=en_us&edition=fundamental","pubTime":"2026-07-01 23:23","pubTimestamp":1782919428,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics  could further de-risk its lead psoriasis drug candidate, ORKA-001, with H2 data expected to show stronger 28-week efficacy than its earlier results and AbbVie's  Skyrizi, UBS Securities said in a Wednesday note.The firm said psoriasis treatments typically show improving efficacy over time. It expects ORKA-001's PASI100 response rate to increase from about 63% at week 16 to 70% to 80% at week 28.UBS said initial one-year durability data should provide an early indication of ORKA-001's potential for six-month or annual dosing. The firm expects the update in late Q3 or Q4, giving the company more time to include one-year data from additional patients.The investment firm also said AbbVie's planned acquisition of Apogee Therapeutics  validates the underlying YTE platform used by ORKA-001 and eases concerns about the intellectual property landscape.UBS maintained its buy rating on Oruka and raised its price target to $130 from $100.Price: 94.44, Change: -0.73, Percent Cha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE000SO60NU8.SGD","IE0000B7K699.USD","IE00B4R5TH58.HKD","LU1003077747.HKD","LU1670627923.USD","LU2237443895.HKD","ABBV","LU0708994859.HKD","LU0069063385.USD","LU1074936037.SGD","LU1244550221.USD","LU0310799852.SGD","SG9999003800.SGD","IE00BDGV0183.EUR","LU0098860793.USD","SG9999015978.USD","LU0158827948.USD","LU1267930573.SGD","LU1732799900.SGD","LU1934455277.USD","BK4139","LU1093756168.USD","LU0861579265.USD","LU0170899867.USD","LU0057025933.USD","BK4550","LU0965509283.SGD","LU2237443622.USD","LU0553294199.USD","ORKA","IE00B3PB1722.GBP","LU0417517546.SGD","LU0122379950.USD","LU1732800096.USD","LU0661504455.SGD","LU0985320562.USD","LU1061106388.HKD","IE00BFTCPJ56.SGD","APGE","LU0203347892.USD","LU1037948897.HKD","LU2129689605.HKD","DBB","LU1551013342.USD","LU2089984988.USD","LU0211328371.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","BK4534","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648510005","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims & Hers Health (HIMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648510005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648510005?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:01","pubTimestamp":1782907265,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims &...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-oruka-therapeutics-orka-and-hims-hers-health-hims-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-oruka-therapeutics-orka-and-hims-hers-health-hims-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2468319806.SGD","HIMS","HMYY","BK4139","LU0889565916.HKD","ORKA","LU1061106388.HKD","IE0002141913.USD","LU1571399168.USD","HIMZ","BK4566","LU2089984988.USD","BK4533","LU0122379950.USD","LU0289739699.SGD","BK4196","LU2242652126.USD","BK4588","IE0009355771.USD","BK4581","HIMY","LU1057294990.SGD","LU0868494617.USD","IE00B2B36J28.USD","AMGN","04332","BK4534","LU1023059063.AUD","HIYY","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4599","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU0109394709.USD","LU0058720904.USD","IE00BJT1NW94.SGD","LU1983299246.USD","LU2112291526.USD","IE00B4R5TH58.HKD","LU2242646821.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324081","title":"Stifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647324081?lang=en_us&edition=fundamental","pubTime":"2026-06-29 16:36","pubTimestamp":1782722161,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Oruka Therapeutics today and set a price target of $150.00. Thompson CFA cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","SF","BK4139","BK4127","CFA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645569878","title":"Oruka Therapeutics (ORKA) Is Up 5.1% After Positive Trial Update And Insider Share Sales - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2645569878","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645569878?lang=en_us&edition=fundamental","pubTime":"2026-06-24 02:29","pubTimestamp":1782239353,"startTime":"0","endTime":"0","summary":"Earlier this week, Oruka Therapeutics reported highly positive progress in its clinical trial pipeline for monoclonal antibody treatments targeting psoriasis and other inflammatory conditions, alongside insider share sales by its Senior Vice President of Finance under a pre-arranged Rule 10b5-1 plan.\nThe combination of encouraging clinical advancement, a substantial cash position with no long-term debt, and intense momentum trading interest has sharpened attention on Oruka’s high-risk,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/oruka-therapeutics-orka-is-up-51-after-positive-trial-update","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/oruka-therapeutics-orka-is-up-51-after-positive-trial-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645005774","title":"Oruka Therapeutics SVP Finance Arjun Agarwal disposes of 1,587 common shares worth $127,454.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2645005774","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645005774?lang=en_us&edition=fundamental","pubTime":"2026-06-23 08:00","pubTimestamp":1782172820,"startTime":"0","endTime":"0","summary":"Sales priced at $80.01 to $82.15; direct holdings fell to 15,312 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL6WbjvT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka Therapeutics SVP Finance Arjun Agarwal disposes of 1,587 common shares worth $127,454.28","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643781401","title":"Oruka Therapeutics CMO Joana Goncalves disposes of USD 552,429 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2643781401","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643781401?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:55","pubTimestamp":1781564104,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Chief Medical Officer Joana Goncalves reported option exercises totaling 7,000 shares on June 15, 2026 at $6.84 and $7.8.Goncalves reported open-market sales totaling 7,000 shares on June 15, 2026 at weighted-average prices of $68.38 to $70.62.She also sold 947 shares at $69.69 under an automatic sell-to-cover process tied to tax withholding.Directly held common stock ended at 32,718 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely respon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL4GQG7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka Therapeutics CMO Joana Goncalves disposes of USD 552,429 common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643034201","title":"Oruka’s Expanded IL-23 Rights Reshape Pipeline Options And Partner Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2643034201","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643034201?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:13","pubTimestamp":1781532803,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (NasdaqGM:ORKA) has amended its IL-23 License Agreement with Paragon Therapeutics.\nThe revised agreement broadens therapeutic, prophylactic, palliative, and diagnostic uses tied to Oruka’s IL-23 pipeline.\nThe amendment also changes certain restrictions related to clinical trials and future licensing terms.\n\nFor Oruka Therapeutics, a company focused on IL-23 directed therapies, this move widens the scope of how its existing science can be used across disease treatment,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/orukas-expanded-il-23-rights-reshape-pipeline-options-and-pa","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/orukas-expanded-il-23-rights-reshape-pipeline-options-and-pa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643454162","title":"Oruka Therapeutics (ORKA) Stock Valuation After A 147% Year-To-Date Surge And 8.7x P/B Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2643454162","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643454162?lang=en_us&edition=fundamental","pubTime":"2026-06-14 13:17","pubTimestamp":1781414265,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) stock has drawn attention after a strong run over the past year, with the share price last closing at $69.89 and market value around $4.2b.\nSee our latest analysis for Oruka Therapeutics.\nThe recent move to $69.89 caps a strong run, with the share price return of 147.22% year to date and a 1 year total shareholder return of about 4.6x pointing to strong momentum rather than a short term spike.\nIf you are looking beyond Oruka Therapeutics, this could be a good moment...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/oruka-therapeutics-orka-stock-valuation-after-a-147-year-to","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/oruka-therapeutics-orka-stock-valuation-after-a-147-year-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218425","title":"Oruka Therapeutics director Carl Dambkowski disposes of $2.46 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218425","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218425?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:37","pubTimestamp":1781296644,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics director Carl Dambkowski sold 35,000 common shares on June 11-12.Sales priced at about USD 70.13 per share on June 11, about USD 70.11 on June 12.Holdings fell to 38,743 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL4QG94p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka Therapeutics director Carl Dambkowski disposes of $2.46 million in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641173663","title":"Is Oruka’s Broadened IL-23 License Reshaping Optionality And Altering The Investment Case For Oruka Therapeutics (ORKA)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2641173663","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641173663?lang=en_us&edition=fundamental","pubTime":"2026-06-07 13:16","pubTimestamp":1780809405,"startTime":"0","endTime":"0","summary":"In June 2026, Oruka Therapeutics, Inc. amended its IL-23 License Agreement with Paragon Therapeutics, expanding ORKA-001’s permitted uses to all therapeutic, prophylactic, palliative, and diagnostic applications, while imposing staged restrictions on clinical trial dosing for inflammatory bowel disease through 2030.\nThis broadened field, combined with conditional relaxation of certain limits following any material transaction or change of control, materially increases Oruka’s optionality in...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/is-orukas-broadened-il-23-license-reshaping-optionality-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/is-orukas-broadened-il-23-license-reshaping-optionality-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AI","ARTY","BK4023","AGIX","AIPO","BK4588","ORKA","BK4551","BK4587","CHAT","AIYY","BK4585","BK4528","BK4543","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641162444","title":"Oruka Therapeutics shareholders elect Klein, Martin as Class II directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2641162444","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641162444?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:19","pubTimestamp":1780604352,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics held its annual shareholder meeting on June 2, 2026.Shareholders selected Lawrence Klein, Chris Martin as Class II directors, with terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL3rkggY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640107739","title":"Piper Sandler Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640107739","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640107739?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:55","pubTimestamp":1780401323,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Oruka Therapeutics today and set a price target of $180.00. Rahimi covers the Healt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-oruka-therapeutics-orka-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-oruka-therapeutics-orka-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964819","title":"Oruka Therapeutics - Enters First Amendment to Il-23 License Agreement With Paragon Therapeutics - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964819?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:04","pubTimestamp":1780344277,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN4290R1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964816","title":"Oruka Therapeutics - Amendment Expands Field to All Uses With Dosing Restrictions for Inflammatory Bowel Disease - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964816?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:04","pubTimestamp":1780344277,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN4290R1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638567644","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Alcon (ALC) and Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638567644","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638567644?lang=en_us&edition=fundamental","pubTime":"2026-05-26 11:40","pubTimestamp":1779766806,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alcon (ALC) and Oruka Therapeutics (ORKA). Alcon (ALC) Stifel Nic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alcon-alc-and-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alcon-alc-and-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","LU0029874061.USD","LU0128526141.USD","LU2265009873.SGD","BK4139","BK4534","BK4581","ALC","BK4585","LU1804176565.USD","ORKA","LABU","BK4588","HCSG","BK4198","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637440963","title":"Oruka Therapeutics director Carl Dambkowski sells common shares worth $6.16 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637440963","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637440963?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:54","pubTimestamp":1779483290,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics director Carl Dambkowski sold 105,000 shares on May 21, 2026 at weighted average prices of $58.43 to $59.97.The filing also shows the exercise of options and a warrant for 62,260 shares at prices of $6.84, $7.8, and $11.77.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL8wpzR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka Therapeutics director Carl Dambkowski sells common shares worth $6.16 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636300415","title":"Oruka SVP Finance Arjun Agarwal sells common shares worth $599,263.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2636300415","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636300415?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:08","pubTimestamp":1779142121,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics SVP, Finance Arjun Agarwal reported option exercises on May 18, 2026, acquiring 7,833 common shares at prices of USD 12.5 to USD 34.39.He also reported selling 10,290 common shares the same day at weighted average prices of USD 58.34 to USD 61.16.Beneficial ownership stood at 16,406 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL12BpBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka SVP Finance Arjun Agarwal sells common shares worth $599,263.29","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.orukatx.com","stockEarnings":[{"period":"1week","weight":-0.0164},{"period":"1month","weight":0.5428},{"period":"3month","weight":0.5984},{"period":"6month","weight":2.0141},{"period":"1year","weight":5.7573},{"period":"ytd","weight":1.8113}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.352941,"avgChangeRate":0.043718},{"month":2,"riseRate":0.388889,"avgChangeRate":-0.070079},{"month":3,"riseRate":0.388889,"avgChangeRate":-0.00265},{"month":4,"riseRate":0.611111,"avgChangeRate":0.112851},{"month":5,"riseRate":0.5,"avgChangeRate":0.08077},{"month":6,"riseRate":0.333333,"avgChangeRate":0.460115},{"month":7,"riseRate":0.5,"avgChangeRate":0.018447},{"month":8,"riseRate":0.117647,"avgChangeRate":-0.132304},{"month":9,"riseRate":0.352941,"avgChangeRate":-0.05799},{"month":10,"riseRate":0.470588,"avgChangeRate":-0.023177},{"month":11,"riseRate":0.647059,"avgChangeRate":0.007168},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.002826}],"exchange":"NASDAQ","name":"ORUKA THERAPEUTICS INC","nameEN":"ORUKA THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ORUKA THERAPEUTICS INC(ORKA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ORUKA THERAPEUTICS INC(ORKA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ORUKA THERAPEUTICS INC,ORKA,ORUKA THERAPEUTICS INC股票,ORUKA THERAPEUTICS INC股票老虎,ORUKA THERAPEUTICS INC股票老虎国际,ORUKA THERAPEUTICS INC行情,ORUKA THERAPEUTICS INC股票行情,ORUKA THERAPEUTICS INC股价,ORUKA THERAPEUTICS INC股市,ORUKA THERAPEUTICS INC股票价格,ORUKA THERAPEUTICS INC股票交易,ORUKA THERAPEUTICS INC股票购买,ORUKA THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ORUKA THERAPEUTICS INC(ORKA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ORUKA THERAPEUTICS INC(ORKA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}